Lorvotuzumab mertansine

Drug Profile

Lorvotuzumab mertansine

Alternative Names: BB-10901; huN901-DM1; huN901-DM1 antibody; huN901-SPP-DM1; IMGN-901; IMGN901 TAP; Monoclonal antibody huN901-DM1 conjugate

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD56 antigen inhibitors; Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Merkel cell carcinoma; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haematological malignancies
  • No development reported Multiple myeloma; Solid tumours
  • Discontinued Small cell lung cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma in Argentina (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top